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Abstract
Jaagsiekte retrovirus (JSRV) causes ovine pulmonary adenocarcinoma (OPA), a transmissible lung cancer of sheep. The envelope (Env)
glycoprotein protein of JSRV functions as a dominant oncoprotein in vitro and in vivo. An SH2 binding domain (YXXM) in the cytoplasmic tail
of the JSRV Env is one of the main determinants of viral transformation at least in vitro. In these studies, we report the first in vivo tests of site-
specific mutants of JSRV in their natural host, the sheep. We show that, in vivo, JSRV21 with the cytoplasmic tail YXXM mutated to DXXM did
not cause disease nor detectable infection, indicating that this motif is absolutely required for virus replication and possibly transformation in vivo.
In contrast, mutation of the JSRV open reading frame orfX, for which no function has yet been attributed, did not alter the disease induced by
JSRV21.
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Jaagsiekte sheep retrovirus (JSRV) is the causative agent of
ovine pulmonary adenocarcinoma (OPA), an infectious lung
tumor of sheep. The disease is of interest both as a real
veterinary problem, and as a potential model for some human
lung adenocarcinomas (Perk and Hod, 1982; Palmarini and Fan,
2001; Mornex et al., 2003). In recent years we and others have
investigated the mechanism of oncogenesis by JSRV using in
vitro systems. JSRV itself does not replicate efficiently in cell
culture, but expression of the JSRVenvelope glycoprotein (Env)
is able to morphologically transform various cell lines including
rodent fibroblast and epithelial cells, and human lung epithelial
cells (Allen et al., 2002; Chow et al., 2003; Danilkovitch-
Miagkova et al., 2003; Liu and Miller, 2005; Maeda et al., 2001;
Palmarini et al., 2001; Rai et al., 2001). Thus, JSRV Env⁎ Corresponding author. Fax: +44 131 445 6111.
E-mail address: chris.cousens@moredun.ac.uk (C. Cousens).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.06.004appears to function as an oncogene, a unique situation for
mammalian oncogenic retroviruses.
We found that the in vitro transforming activity of JSRV Env
is dependent on the short cytoplasmic tail of the C-terminal
transmembrane (TM) domain. In particular, a single tyrosine at
position 590 is critical since mutation of this residue (Y590F,
Y590D or Y590A) abolishes transformation in rodent cells
(Hull and Fan, 2006). The Y590 is in the sequence motif
YXXM, which if phosphorylated could bind the SH2 domain of
the p85 regulatory subunit of phosphatidyl inositol 3-kinase
(PI3K). Indeed, constitutive phosphorylation of Akt, a down-
stream substrate of PI3K, was detected in JSRV-transformed
rodent fibroblasts; the phosphorylation was blocked by PI3K
inhibitors or mutation of Y590 (Alberti et al., 2002; Palmarini et
al., 2001). However, Y590 has not been found phosphorylated
in Env-transformed cells and there is no evidence of p85
binding the JSRV Env. In addition some cell lines such as the
chicken fibroblast line DF-1, transformation by JSRV Env does
not absolutely require Y590 (Allen et al., 2002) although trans-
Fig. 1. Replication capacity of JSRVΔorfX. Sheep choroid plexus cells (CP-1)
were infected with (i) heat-inactivated JSRV21, (ii) JSRV21, (iii) heat-
inactivated ΔorfXJSRVor (iv) ΔorfXJSRV, and serially passaged. At different
passages DNAwas extracted from the cells and tested by PCR for the presence
of proviral JSRV DNA. Representative PCR results from an intermediate
passage are shown (ca. passage 6); PCR signals for both wild-type and ΔorfX
JSRV were detectable at equivalent levels through passage 23. No PCR signals
were detected in the cultures infected with heat-inactivated viruses. +: PCR
positive control, pCMV2JS21 plasmid DNA. −: PCR negative control, water.
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ylation can be detected in vivo in tumors induced by the related
enzootic nasal tumor virus (ENTV), but only in some OPA
tumors (Zavala et al., 2003; Suau et al., 2006). Thus the
importance of the Y590 residue for JSRV oncogenesis in vivo
remains to be determined.
JSRV carries an alternate reading frame within the pol gene,
designated orfX (York et al., 1992). This reading frame is
conserved in all exogenous JSRV isolates sequenced to date and
also in some of the JSRV-related sheep endogenous retroviruses
present in normal sheep (Palmarini et al., 2000; Rosati et al.,
2000). Caprine ENTV (ENTV-2) also has an open orfX reading
frame, but there are two stop codons in the orfX reading frame
of ovine ENTV (ENTV-1) (Cousens et al., 1999). orfX has an
unusual codon usage, which suggests that the putative protein
may be expressed at low levels. Weak amino acid similarity of
the putative OrfX protein to the adenosine A3 receptor has been
noted (Bai et al., 1999). The OrfX peptide has proven difficult
to express in vitro, so it has not been possible to raise antisera
that might detect expression of the protein in infected cells or
tumors. We detected a 3.2 Kb spliced JSRV RNA in OPA
tumors and transiently transfected 293T cells containing the
entire orfX reading frame which could be the mRNA for this
protein (Palmarini et al., 2002).
We previously generated a mutant molecular clone of JSRV
DNA containing two stop codons in the orfX reading frame
without altering the amino acids in the overlapping pol frame
(Maeda et al., 2001). In in vitro transformation assays, this
mutant gave the same number of transformed foci in NIH-3T3
cells as the parental wild-type JSRV DNA clone (Maeda et al.,
2001). Thus orfX protein does not appear to be involved in the
oncogenic properties of JSRV, but this did not rule out effects on
virus replication.
Given the lack of an efficient cell culture system for the
propagation of JSRV we cannot test in vitro viral mutants. In
these studies, we report the first in vivo tests of site-specific
mutants of JSRV in their natural host, the sheep. Our previous
isolation of an infectious and oncogenic molecular clone of
JSRV, and development of methods to prepare infectious virus
from it, made this possible (Palmarini et al., 1999a). In this
report, mutants in env (Y590D) and in orfX were studied.
Results
Generation of infectious JSRV mutants in orfX or env
To test the potential importance of the orfX and the Y590
residue of the JSRV Env in oncogenesis in vivo, it was first
necessary to generate infectious JSRVs containing mutations in
these genes. We previously isolated a complete integrated JSRV
provirus (clone 21) from an OPA tumor and showed that placing
the viral sequences under control of the highly active human
cytomegalovirus (CMV) immediate early promoter allowed
production of infectious virus by transient DNA transfection of
human 293T cells (Palmarini et al., 1999a). The availability of
this virus allowed us to establish an in vitro infection system for
JSRV in sheep choroid plexus (CP) cells and other ovine celllines (Palmarini et al., 1999b), although infection was
inefficient due to the fact that the JSRV is transcriptionally
specific for lung epithelial cell lines, and no ovine lung
epithelial lines that retain their differentiation properties exist.
In vitro, infectivity could be assessed by infection of CP cells,
followed by serial passage of the infected cultures and PCR
analyses for JSRV DNA at different passages.
We previously described a mutant form of the CMV-driven
JSRV proviral plasmid in which two stop codons were created
in the orfX reading frame by single base mutations that did not
affect the amino acids in the corresponding parts of the integrase
protein (pCMV2JS21ΔorfX, Maeda et al., 2001). We showed
that pCMV2JS21ΔorfX is capable of transforming NIH-3T3
cells in culture, indicating that the putative orfX protein is not
necessary for transformation (Maeda et al., 2001). We tested if
JSRV virus with the orfX mutation is infectious in vitro. JSRV
ΔorfX was prepared by transient transfection of 293T cells, and
then tested for infection of CP cells (Fig. 1). Compared to CP
cells infected with wild-type JSRV, similar amounts of JSRV
DNA could be detected in cells infected with JSRVΔorfX, even
after prolonged passage (23 passages). In contrast, infection of
CP cells with heat-inactivated viruses resulted in no PCR
amplification products, indicating that the positive PCR signals
represented genuine viral infection. These results indicated that
orfX protein is not necessary for JSRV replication in vitro, and
they provided a means for generation of orfX mutant virus.
We have extensively studied the JSRV Env protein and its
role in in vitro transformation of rodent cells (Alberti et al.,
2002; Chow et al., 2003; Hofacre and Fan, 2004; Hull and
Fan, 2006; Maeda et al., 2003, 2005; Palmarini et al., 2001;
Zavala et al., 2003). For the transformation studies, we used a
CMV-driven Env expression plasmid derived from
pCMV2JS21 that only encodes Env protein, pCMV3ΔGP
(Maeda et al., 2001). Previous site-directed mutagenesis
experiments indicated that a YXXM motif (putative binding
site for the p85 subunit of phosphatidyl inositol 3-kinase
[PI3K]) is essential for efficient transformation in mouse and
rat cells (Hofacre and Fan, 2004; Maeda et al., 2005;
Palmarini et al., 2001). In particular, mutation of the YXXM
tyrosine residue (Y590F or Y590D) abolished or greatly
reduced transformation (Palmarini et al., 2001). To test if these
Env mutations allowed production of infectious virus, they
were transferred from pCMV3ΔGP to pCMV2JS21, to give
Fig. 2. Comparison of JSRV dose in the inocula. (a) Western blot comparison of
JSRV. 5 μl of inoculum run on a 10% SDS-PAGE gel, electro blotted onto
nitrocellulose and reacted with 1:200 antiserum JS382 (raised against
recombinant JSRV CA protein Salvatori et al., 2004). (b) qRT-PCR estimation
of JSRV copy number. Serially diluted in vitro transcribed RNA was used as
standard from which to estimate the RNA copy number of the JSRV in 5 ml of
inoculum. Error bars shown are the standard error of the mean from four
replicates.
Table 1
Summary of results of in vivo inoculation with JSRV
Inoculum No. of
animals
inoculated
No. of animals
with OPAa in
≤9 months
No. of
animals
producing LF
Clinical signs
first noted in
some animals
JSRV21-03 20 17 5 6 weeks
TMY590D-03 20 0 0 n/a
JSRV21-04 10 10 6 7 weeks
ΔorfX-04 12 11 8 7 weeks
a Animals noted with OPA lesions at histopathological examination of post
mortem lung samples.
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TMY590D. Mutant viruses were then obtained by transient
transfection of the proviral plasmids into 293T cells, and they
were then tested for replication in vitro in CP cells as described
above. Both mutant viruses were capable of replication in CP
cells, as evidenced by positive PCR signals in the infected
cultures. However, the PCR signal for JSRV TMY590F was lost
after 3–4 cell transfers, while the PCR signal for JSRV
TMY590D persisted for the same number of transfers as for
cultures infected with wild-type JSRV (N6 transfers). These
results indicated that the Y590F mutation in TM reduced
infectivity of the virus, while Y590D mutation did not appear to
show this defect within the limitations of the assay. Therefore,
JSRV TMY590D was chosen for in vivo studies.
Generation and quantification of JSRV stocks
Viral stocks of wild-type and mutant JSRVs were prepared
by large-scale transient transfection of 293Tcells as described in
Materials and methods. Two preparations of wild-type JSRV
were generated, one in parallel with JSRV ΔorfX for one
experiment (JS21-04) and one in parallel with JSRV TMY590D
for the other experiment (JS21-03). During the transient
transfections, the relative amounts of the wild-type and mutant
viruses produced on the different days of harvest were
monitored by SDS-PAGE and western blotting for JSRV CA
protein (26 kDa) (Fig. 2). The amount of JSRVΔorfX produced
by the transfected cells was similar to that for wild-type JSRV
(top panels). On the other hand, the amount of JSRV TMY590Dwas consistently less than that produced by the wild-type JSRV-
producing cultures (ca. ten-fold less, lower panels). Therefore,
more transfected cultures and higher degrees of concentration
were used to generate the JSRV TMY590D stocks; they were
adjusted to the concentration of the wild-type JSRV stock based
on western blotting for JSRV CA.
Subsequent to the experimental inoculations, we developed a
quantitative RT-PCR assay for JSRV RNA (Cousens et al., in
preparation), and it was applied to the viral inocula as an
independent measure of the amounts of virus inoculated. The
results indicated that in the first experiment comparing wild-
type and TMY590D JSRV, the amounts of viral RNA in the
inocula were equivalent; in the second experiment comparing
wild-type and ΔorfX JSRV, the amount of JSRV ΔorfX RNA
was approximately five-fold higher than wild-type JSRV RNA
(Fig. 2). Thus fairly well-matched inocula were used in the
experiments. All inocula were checked by RT-PCR amplifica-
tion and sequencing of the regions encompassing the mutations.
For the mutant viruses, the expected mutations were detected,
and there was no evidence for the presence of wild-type JSRV in
the stocks.
In vivo infection with JSRV TMY590D
In the first experiment, twenty newborn (1–7 days old)
lambs from an OPA-free flock were inoculated intra-tracheally
with wild-type JSRV (stock JS21-03), and the same number of
animals were inoculated with an equivalent amount of JSRV
TMY590D (stock Y590D-03) (Table 1). Sixteen of the wild-
type JSRV-inoculated animals appeared to show early signs of
OPA between 6 and 12 weeks p.i. and were sacrificed and
necropsied. OPAwas confirmed by histopathology in 14 out of
the sixteen animals. The remaining four animals were sacrificed
and analyzed at 9 months p.i., and three of them were confirmed
to have OPA. Thus in total at least 17/20 of animals inoculated
with the cloned JSRV21 stock developed OPA by 9 months.
None of the animals inoculated with JSRV TMY590D
showed symptoms of OPA over the course of the experiment
(9 months). One animal was sickly and was euthanized at
3 weeks of age. Eight animals were sacrificed and necropsied at
6 months p.i., and the remainder at 9 months. None of the
animals showed evidence of OPA upon histological examina-
tion. This would be consistent with the TMY590D mutation
abolishing in vivo oncogenicity for the virus. To test if JSRV
TMY590D could replicate in vivo, we tested blood at various
Fig. 3. Histology of experimentally-induced OPA. Haematoxylin and eosin
stained sections of OPA induced by (a) JSRV21 and (b) JSRVΔorfX show
indistinguishable tumors composed of papillary proliferation of cuboidal
epithelial cells in the lung parenchyma irrespective of whether they were
induced by the wild-type or Δorfx virus.
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mortem for the presence of viral DNA by PCR (Salvatori et al.,
2004). We have previously found that low levels of infected
cells in the blood can be detected by PCR in animals
experimentally inoculated with JSRV (Holland et al., 1999;
Palmarini et al., 1996; Salvatori et al., 2004) and this can be
taken as an indicator of productive in vivo infection. Likewise,
some blood samples from animals naturally-infected with JSRV
test positive by PCR, but this is highly variable when
longitudinal samples from the same animal are tested (D.
Salvatori PhD thesis; Caporale et al., 2005; De las Heras et al.,
2005; Gonzalez et al., 2001). Even though sequencing
confirmed the presence of only the Y590D mutation in the
input inoculum, when PCR amplification products from the env
gene from the blood of the infected animals were sequenced, in
all cases they showed sequences corresponding to wild-type
JSRV env and not the Y590D mutant. One possible explanation
could be contamination during the PCR amplification, even
though results were only considered when appropriate prepara-
tion and PCR control samples were negative. Another
explanation could be that the Y590D mutant virus was defective
for replication in vivo and there was in vivo selection for
reversion of the Y590D mutation to wild-type Env. However,
PCR from Y590D-infected lambs yielded wild-type Env even
in blood taken 1 day post-infection. This seems too short a time
for the appearance of wild-type revertants. Thus contamination
during the PCR amplification must be seriously considered
although we cannot rule out infection by wild type JSRV of
some of our housed sheep although no OPA cases have been
recorded in the flock since it was purchased 7 years ago.
To try to find conclusive evidence of infection with JSRV
TMY590D, samples of mediastinal lymph node (MLN)
collected at post mortem examination were tested by PCR for
the presence of JSRV. None of 20 TMY590D-inoculated
animals tested contained detectable JSRV in MLN samples.
Taken together with the PCR amplifications on infected animal
blood, there was no evidence for infection in vivo by JSRV
TMY590D.
In vivo infection with JSRV ΔorfX
In the second experiment, ten newborn lambs were
inoculated intratracheally with wild-type JSRV (stock JS21-
04) and twelve animals were inoculated with JSRV ΔorfX
(stock ΔorfX-04) (Table 1). The clinical pictures of both groups
were very similar. Early clinical signs were first noted in both
groups at around 7 weeks of age. All the animals were culled
over the next 8 weeks as clinical signs became more noticeable.
The last animals were culled at 15 weeks p.i. Histopathology
confirmed OPA in all 10 JSRV21-inoculated animals and in 11
of the 12 animals inoculated with JSRV ΔorfX. There was no
discernable difference in the pathology caused by the two
viruses (Fig. 3). Lung fluid was collected at post mortem from 7
of the 12 animals inoculated with JSRV ΔorfX, and 7 of the 10
inoculated with JSRV21. The volumes collected varied from 2 to
40 ml. By comparison, lung fluid collection from naturally
occurring field cases of OPA may be from 0 to 500 ml of lungfluid per day. Large volumes of lung fluid are generally asso-
ciated with more extensive tumor lesions, while the experimen-
tally inoculated animals typically had multiple small lesions.
To test if the inoculated JSRV ΔorfX mutant virus itself had
induced disease and was being produced by the tumor, RNAs
from lung fluids from two animals inoculated with this virus
were extracted and amplified by RT-PCR. Sequencing of the
amplicons indicated the presence of both mutations in the JSRV
ΔorfX virus (Table 2). As expected, equivalent analysis of lung
fluids from two animals inoculated with wild-type JSRV21
showed the predicted wild-type sequences. These results
therefore indicate that mutation of the orfX reading frame
does not interfere with either in vivo replication or oncogenesis
by JSRV.
Comparative quantitation of the inocula used for the in vivo
experiments is shown in Fig. 2 and a summary of the outcome
of these inoculations is shown in Table 1.
Discussion
In the studies reported here, we tested for the first time the
biological activities of JSRV mutants in vivo in their native host,
Table 2
Sequence of JSRV around orfX point mutations
Source Sequence at 5′ site Sequence at 3′ site
♦ ♦
JSRV21 CCTCAAACCCTTAAGACAGA TTTGGACGTCTTAAATATGT
ΔorfX CCTCAAACCCTAAAGACAGA TTTGGACGTCTAAAATATGT
enJSRVa CCTCAAACCCTTAAGACAGA TTTGGACGTCTTAAATATGT
A357b-LF CCTCAAACCCTAAAGACAGA TTTGGACGTCTAAAATATGT
A385b-LF CCTCAAACCCTAAAGACAGA TTTGGACGTCTAAAATATGT
A361c-LF CCTCAAACCCTTAAGACAGA TTTGGACGTCTTAAATATGT
A362c-LF CCTCAAACCCTTAAGACAGA TTTGGACGTCTTAAATATGT
a JSRV-like endogenous sheep retrovirus. Lung fluid (LF) produced by animals inoculated with b JSRV-ΔorfX or c JSRV21.
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an infectious molecular clone of JSRV (JSRV21), and develop-
ment of the transient transfection approach for recovering
infectious virus (Palmarini et al., 1999a). Given the logistic and
cost challenges of performing in vivo experiments on large
animals, the use of an in vitro infectivity assay as a preliminary
screen for replicative ability of viral mutants was also
important. These experiments describe in vivo tests of JSRV
mutants in the YXXM motif in the cytoplasmic tail of the
envelope TM protein (important for efficient transformation or
rodent cells in vitro), and in the orfX reading frame that is
conserved among all JSRV isolates but for which a function has
not been assigned.
In the first experiment, we tested if mutation of the TM
cytoplasmic tail YXXM motif led to loss of tumorigenesis for
JSRV, as might be predicted from the in vitro transformation
experiments. Indeed, lambs inoculated with JSRV TMY590D
did not develop OPA, which would be consistent with this
hypothesis. The Y590D mutant was selected because in the in
vitro infection assay, it showed replication equivalent to wild-
type JSRV while the Y590F mutant showed a replication
defect. If animals infected with JSRV TMY590D showed
evidence for infection but no tumors, this would have strongly
supported the importance of the YXXM motif in the TM
cytoplasmic tail in lung tumorigenesis. The input inoculum
was confirmed to contain the Y590D mutation but the only
virus that could be detected in these animals was of wild-type
sequence and it is therefore questionable whether this
represents genuine infection. Reversion would be relatively
feasible, since the Y590D mutation was due to a single base
change, but wild type sequence was detected as early as day
1 p.i., so sample contamination during the PCR must be
strongly considered. A possible explanation for our inability to
detect virus with the Y590D mutation in these animals is that it
did not efficiently replicate in vivo. As shown in Fig. 2, the
amount of Y590D virus produced from transiently transfected
293T cells was substantially less than from cells producing
wild-type virus. This would be consistent with a replication
defect in vivo, even though within the limits of the assay, the
in vitro infectivity assay did not indicate a defect. In the
related betaretrovirus Mason–Pfizer monkey virus (MPMV),
the cytoplasmic tail of TM contains a tyrosine residue in the
analogous location to the Y590 for JSRV TM, and mutation of
the MPMV tyrosine results in defects in transport/release ofcytoplasmic viral core particles from the cells (Blot et al.,
2006) At the very least, the experiments with JSRV TMY590D
indicate that the Y590 residue is essential for tumorigenesis
and/or replication of JSRV. It may be that cell transformation
or enhanced cell division is necessary for efficient production
and spread of JSRV. In the future it might be interesting to test
other non-transforming TM cytoplasmic tail mutants to see if
they are not tumorigenic. We have carried out alanine scanning
mutagenesis of the cytoplasmic tail, and identified quite a
number that do not transform cells in vitro (Hull and Fan,
2006). We have generated pCMV2JS21 plasmids containing
each of these mutations and found that the majority of them
(unlike JSRV TMY590D) produce the same amounts of virus
during transient transfections of 293T cells. It will be
interesting to test if any of the JSRVs with non-transforming
mutations in the TM cytoplasmic tail show replication
equivalent to wild-type JSRV in the in vitro infection of CP
cells. If a mutant with a non-transforming env gene shows
normal levels of virus production and replication in vitro, it is
possible that such a mutant would show in vivo replication but
no tumorigenesis. We also identified alanine substitutions in
the TM cytoplasmic tail that showed enhanced transformation
in vitro (Hull and Fan, 2006). It would be interesting to
investigate if such mutants show enhanced tumorigenicity in
animals.
The goal of the in vivo test of JSRV TMY590D was to
determine if the JSRV Env protein is functioning as an
oncogene in JSRV-induced OPA. After these experiments
were initiated, two experiments have strongly confirmed this
hypothesis. Wootton et al. (2005) showed that infection of
immunodeficient mice with an adeno-associated virus (AAV)-
based vector expressing the JSRV Env protein developed lung
adenocarcinomas with histopathology reminiscent of OPA. In
addition, we generated a JSRV-based vector expressing only
the Env protein, and showed that inoculation of the vector
into newborn lambs resulted in development of OPA (Caporale
et al., 2006).
The experiment with JSRV ΔorfX showed that this virus
induced OPA with a similar time course and histopathology
compared to wild-type JSRV (Fig. 3). This confirmed the
indications from the in vitro experiments that orfX is not
required for in vivo replication or transformation by JSRV.
However, it was still possible that a truncated orfX protein
could be contributing to these processes, since JSRV ΔorfX
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chosen as these were sites where stop codons could be
introduced into orfX without altering the amino acid sequence
of the overlapping pol gene. Interestingly, ovine enzootic nasal
tumor virus (ENTV-1) has stop codons in exactly the same
places as those engineered into JSRV ΔorfX (Cousens et al.,
1999).
These experiments provided the first large-scale evaluation
of the in vivo tumorigenicity of molecularly cloned JSRV.
Originally, induction of JSRV-induced OPA employed JSRV
inocula derived from concentrated lung fluids from animals
with OPA (Martin et al., 1976; Salvatori et al., 2004; Summers
et al., 2002, 2005). These previous studies showed induction of
OPA within weeks-to-months, although in some cases induc-
tion of disease has been less efficient (J.M. Sharp, personal
communication). In a previous infection with cloned JSRV21, 2
out 4 animals developed OPA after 4 months (Palmarini et al.,
1999a). This might have suggested that the cloned JSRV was
less oncogenic or infectious than lung fluid-derived JSRV.
Therefore in the first experiment described here, 20 animals
were infected with wild-type JSRV21 as the positive control.
As described, 17/20 of the JSRV21-inoculated lambs developed
OPA. Consequently, in the second experiment, a reduced
number of animals were infected with JSRV21 or JSRV ΔorfX.
Combining the results with JSRV21 in the first and second
experiments, it can be predicted that 92.5±10.6% of animals
(at least of the age and breed utilized in this study) will
develop OPA when inoculated with the concentration of
JSRV21 used here under these experimental conditions.
Although quantification of viral RNA in the inocula did not
necessarily measure infectious virus, it appeared to be a
reasonable way of equalizing virus dose within and between
experiments. The results from these large scale in vivo
experiments will allow better predictions of outcomes in
future studies, resulting in using smaller groups of animals
while maintaining statistical power, in line with the aims of the
3Rs in animal experimentation (Flecknell, 2002; Russell and
Burch, 1959).
Post mortem examinations showed that OPA tumors with
discrete lesions had developed in the wild-type and JSRV
ΔorfX-inoculated animals within a few weeks of infection. On
the other hand, two animals suspected of having early physical
symptoms of OPA did not show evidence of tumors by
histopathology. This may have been because we were looking
for subtle early signs of OPAwhich may be similar to symptoms
of other lung infections. A recent field study also found that it
was not possible to identify early stage OPA from clinical signs,
and even late stage OPA may be misdiagnosed prior to post-
mortem examination (Cousens et al., in press).
In summary, this study demonstrated the efficacy of the
JSRV21 experimental OPA system as a model to test JSRV
pathogenicity in vivo. We showed that a complete orfX is not
required for pathogenesis of JSRV. We also showed that
mutation of Y590, part of the YXXM motif of envTM which is
predicted to be involved in transformation by JSRV, appears to
abrogate the ability of the virus to replicate and/or cause tumors
in vivo.Materials and methods
Vector constructs
Generation of the infectious molecular clone pCMV2JS21
has been described previously (accession number AF105220)
(Palmarini et al., 1999a). The TM mutant, JSRV21TM-Y590D,
has a single nucleotide substitution changing the tyrosine at
position 590 to aspartic acid (Palmarini et al., 2001). TheΔorfX
mutant of pCMV2JS21 has been described previously (Maeda
et al., 2001); two T to A substitutions in the orfX region (nt
4565–5104) generate two stop codons in this reading frame (at
4821 TTA to TAA and at 4952 TTA to TAA) without altering
the amino acid sequence encoded by the overlapping region of
the pol gene.
In vitro virus production
Human 293Tcells (3.2×106 cells per 10 cm plate) in 10 ml of
D-MEM/10%FBS/Penicillin/Streptomycin were seeded
approximately 24 h before transfection. Cells were transfected
with 28 μg per plate pCMV2JS21 (Palmarini et al., 1999a) using
the CalPhos Mammalian Transfection Kit (Clontech) as per
manufacturer's instructions. After 12 h the transfection medium
was replaced with 5 ml culture medium. Culture medium was
harvested 24, 48 and 72 h later. At each time point the super-
natant was filtered (0.45 μM filters) and virus was concentrated
by centrifugation (100,000 g for 1 h at 4 °C) on 50% and 25%
glycerol cushions as described previously (Palmarini et al.,
1999a). Pellets were resuspended in 0.1 M NaCl, 0.01 M Tris
(pH 7.5), 1 mM EDTA (one hundredth original volume) and
stored at −70 °C. Immediately prior to inoculation the con-
centrated stocks were pooled and adjusted to 66 ml with PBS.
In vitro infection
Sheep choroid plexus cells (CP-1) were infected with wild-
type or ΔorfX mutant JSRV produced from transfected 293T
cells as described previously (Palmarini et al., 1999a). In
parallel, virus that had been heat-inactivated (15 min at 65 °C)
was also infected into CP-1 cells. The infected cell cultures were
serially passaged, and at different passages were DNA from cell
extracts was tested for the presence of exogenous JSRV DNA
by PCR employing primers P-I (TGGGAGCTCTTTGGCAA-
AAGCC) and P-III (CACCGGATTTTTACACAATCACCGG)
(Palmarini et al., 1996).
Experimental infection
JSRV TMY590D
One to 7-day-old lambs from a known OPA-free flock were
inoculated with 5 ml of virus stock by the intratracheal route.
Twenty lambs each received the equivalent of ten 10 cm plates
per animal (all 3 harvests) of JSRV21. Twenty lambs each
received equivalent amounts of JSRV21 TMY590D based on
western blots for viral CA protein. Aliquots of the inocula were
stored at −70 °C for subsequent analysis.
419C. Cousens et al. / Virology 367 (2007) 413–421Animals were monitored every 2–3 days for early signs of
OPA by observing respiration at rest and after exercise. Signs of
abnormal breathing and/or slow recovery time were noted.
Animals were euthanized when early OPAwas suspected or at 6
or 10 months old. Blood samples were collected at 1 day,
1 week and 1 month post infection and at monthly intervals
thereafter. Samples of blood, lung fluid (if present), lung tumor,
normal and mediastinal lymph node were collected at necropsy
for histopathological examination and/or for PCR analysis.
When available, lung fluid was collected by raising the
animal's rear end and collecting the fluid dripping from its
nostrils. The lung fluid was prepared as follows: mucus was
removed by filtering through sterile gauze and cells and debris
were removed by centrifuging 1 ml aliquots in a microfuge for
5 min, discarding the pellet and repeating the microcentrifuga-
tion. 100 μl aliquots of clarified lung fluid were stored at
−70 °C.
JSRVΔorfX
Two to 4-day-old lambs from a known OPA-free flock were
inoculated with 5 ml of in vitro produced virus by the
intratracheal route. 10 lambs received the equivalent of seven
and a half 10 cm plates (all 3 harvests) of JSRV21. Twelve
lambs received JSRV21ΔorfX harvested from nine plates.
Aliquots of the inocula were stored at −70 °C for subsequent
analysis. Animals were monitored and lung fluid was collected
as above.
PCR on lymph nodes
The QIAgen tissue kit was used (as manufacturer's
instructions) to extract DNA from lymph nodes collected at
post mortem. PCR tests were performed in triplicate as
previously described (Salvatori et al., 2004). PCR conditions
were as follows: 100 ng of test DNA with 5 μl of 10× PCR
Buffer (Qiagen), 200 μM dNTPs (Roche Diagnostics Ltd., East
Sussex, UK), 200 μMof each primer P-I and P-III and 1.25 U of
Hot Start Taq polymerase (Qiagen) in a final volume of 50 μl.
Cycle conditions were 94 °C for 16 min, followed by 35 cycles
at 94 °C for 30 s, 59 °C for 30 s and 72 °C for 30 s, with a final
extension step of 5 min at 72 °C. PCR products were visualized
following electrophoresis in a 2% agarose gel containing 100 μg
ml ethidium bromide. If any one of the triplicate reactions
generated a product of the correct size the test was considered
JSRV positive.
Quantitation of the inocula
The viral RNA copy numbers in the inocula were compared
using quantitative real-time PCR (Cousens et al., in prepara-
tion). Briefly, virus was prepared using the QIAgen viral RNA
kit according to the manufacturer's instructions and eluting with
100 μl of elution buffer. Single step RT-PCR was conducted as
follows using reagents from the Applied Biosystems real-time
one step RT-PCR kit; (1× reaction buffer, 1× RT, 10 μM each
dNTP), plus 200 nM each primer P-I and P-III, 200 nM
fluorogenic probe JS-T (5′-FAM-AGCAAACATCCGARCCT-TAAGAGCTTTCAAAA-TAMRA-3′), and 4 μl of test or
standard RNA template in a 50 μl reaction volume. Amplifica-
tion, data analysis and data acquisition were carried out on an
ABI Prism SDS 7000 (Applied Biosystems). Cycling condi-
tions were as follows: 48 °C for 30 min, 94 °C for 10 min
followed by 40 cycles of 95 °C for 15 s, 59 °C for 30 s and 60 °C
for 30 s.
Sequence analysis of inocula and experimental samples
RT-PCR followed by sequencing was used to check the
sequence of JSRV in the inocula and in virus produced in lung
fluid of the animals with OPA. Fifty microlitres of clarified lung
fluid or of inoculum was treated with DNase as follows: 0.1 mM
sodium acetate, 2.5 mM MgCl2 5 mM Tris pH 8.5, 2 μl DNase
(RNase free) (Roche) in a total volume of 140 μl, incubated at
30 °C for 1 h then 65 °C for 10 min. RNA was then extracted
using the QIAgen viral RNA kit according to the manufac-
turer's instructions and eluted in 50 μl. Four microliters of RNA
was used for RT-PCR as described below. The product was gel
purified and recovered using the QIAgen gel purification kit
according to the manufacturer's instructions. Sequencing was
done on a MegaBACE 500 using ET terminator chemistry. The
data were processed using the Cimarron 3.12 basecaller.
JSRV TMY590F PCR
Hemi-nested PCR was conducted using primers TMfo
(7004–7034 JSRV21) AAGATGAGAGTTGAAATGCTGCA-
TATG and TMr (complement of 7225–7247) GTAGGAATAC-
TTGTGTTTATTATAATTGTCG in the first round and TMfi
(7086–7101 JSRV 21) GTAYTTGTCCTAGGCTTTGGCTT
and TMr in the second round, to amplify the region of JSRV
containing the Y590D substitution. Reaction conditions were
1× reaction buffer (QIAgen) plus 0.5 mM MgCl2, 0.2 mM each
dNTP, plus 200 nM each primer in a 50 μl reaction volume.
Cycling conditions were as follows: 48 °C for 30 min, 94 °C for
10 min followed by 35 cycles of 95 °C for 30 s, 57 °C for 30 s
and 72 °C for 60 s, with a final extension of 5 min at 72 °C. A
number of the amplimers were sequenced. These were gene-
rated in separate RT-PCR runs from at least 2 independent DNA
extractions for each sample and were sequenced individually.
To check the sequence of the JSRV TMY590D inoculum RT-
PCR was conducted using primers TMf1 and TMr with the one-
step Superscript III RT-PCR kit (Invitrogen) according to the
manufacturer's instructions, and 4 μl of RNA as target. Cycles
were; 50 °C 15 min, 95 °C 2 min then 35 cycles of 95 °C 15 s,
57 °C 30 s.
orfX PCR
DNA fragments spanning the orfXmutations were generated
with primers orfX-f1 TCTGGCAAACAGATGTTACTCAC
(4777–4797 of JSRV21) and orfX-r2 GGCTAGTATACCCA-
GGTCC (C' of 4966–4984) using the one-step Superscript III
RT-PCR kit (Invitrogen) according to the manufacturer's
instructions, and 4 μl of RNA as target. Cycles were as follows:
50 °C 15 min, 95 °C 2 min then 35 cycles of 95 °C 15 s, 58 °C
30 s.
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